CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has successfully closed its underwritten public offering of 2,000,000 shares of common stock, priced at $2.50 per share. The offering generated total gross proceeds of $5 million, prior to the deduction of underwriting discounts and other related expenses. The company has also granted underwriters a 45-day option to purchase an additional 190,000 shares to address over-allotments. The funds raised are intended to support the continued development of Multikine, as well as general corporate purposes and working capital. ThinkEquity served as the sole book-running manager for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.